222 related articles for article (PubMed ID: 25504334)
1. Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.
Yabe M; Ohtsuka Y; Watanabe K; Inagaki J; Yoshida N; Sakashita K; Kakuda H; Yabe H; Kurosawa H; Kudo K; Manabe A;
Int J Hematol; 2015 Feb; 101(2):184-90. PubMed ID: 25504334
[TBL] [Abstract][Full Text] [Related]
2. A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
Yabe M; Sako M; Yabe H; Osugi Y; Kurosawa H; Nara T; Tokuyama M; Adachi S; Kobayashi C; Yanagimachi M; Ohtsuka Y; Nakazawa Y; Ogawa C; Manabe A; Kojima S; Nakahata T;
Pediatr Transplant; 2008 Dec; 12(8):862-7. PubMed ID: 18397212
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11.
Sakashita K; Yoshida N; Muramatsu H; Ohtsuka Y; Watanabe K; Yabe M; Kakuda H; Honda Y; Watanabe T; Haba M; Ohmori S; Matsuda K; Yuza Y; Saito A; Horibe K; Adachi S; Manabe A
Transplant Cell Ther; 2024 Jan; 30(1):105.e1-105.e10. PubMed ID: 37806448
[TBL] [Abstract][Full Text] [Related]
4. Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
Dvorak CC; Satwani P; Stieglitz E; Cairo MS; Dang H; Pei Q; Gao Y; Wall D; Mazor T; Olshen AB; Parker JS; Kahwash S; Hirsch B; Raimondi S; Patel N; Skeens M; Cooper T; Mehta PA; Grupp SA; Loh ML
Pediatr Blood Cancer; 2018 Jul; 65(7):e27034. PubMed ID: 29528181
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation.
Yoshida N; Sakaguchi H; Yabe M; Hasegawa D; Hama A; Hasegawa D; Kato M; Noguchi M; Terui K; Takahashi Y; Cho Y; Sato M; Koh K; Kakuda H; Shimada H; Hashii Y; Sato A; Kato K; Atsuta Y; Watanabe K;
Biol Blood Marrow Transplant; 2020 May; 26(5):902-910. PubMed ID: 31790827
[TBL] [Abstract][Full Text] [Related]
8. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
10. Human leukocyte antigen disparities reduce relapse after hematopoietic stem cell transplantation in children with juvenile myelomonocytic leukemia: A single-center retrospective study from China.
Lin YC; Luo CJ; Miao Y; Wang JM; Luo CY; Qin X; Cai JY; Li BS; Chen J
Pediatr Transplant; 2021 Mar; 25(2):e13825. PubMed ID: 33131184
[TBL] [Abstract][Full Text] [Related]
11. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
[TBL] [Abstract][Full Text] [Related]
12. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of cord blood transplantation for nine children with juvenile myelomonocytic leukemia receiving fludarabine-busulfan-cyclophosphamide-based conditioning.
Li G; Sun Z; Geng L; Wan X; Zhu X; Tang B; Tong J; Yao W; Song K; Qiang P; Zhang L; Zhang X; Zhang S; Liu H
Pediatr Transplant; 2022 Mar; 26(2):e14181. PubMed ID: 34747111
[TBL] [Abstract][Full Text] [Related]
14. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen.
Fedele R; Messina G; Martinello T; Gallo GA; Pontari A; Moscato T; Console G; Dattola A; Princi D; Cuzzola M; Alati C; Ronco F; Molica S; Irrera G; Martino M
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):493-500. PubMed ID: 25034142
[TBL] [Abstract][Full Text] [Related]
18. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
19. Successful hematopoietic stem cell transplantation from an HLA-mismatched parent for engraftment failure after unrelated cord blood transplantation in patients with juvenile myelomonocytic leukemia: Report of two cases.
Akahane K; Watanabe A; Furuichi Y; Somazu S; Oshiro H; Goi K; Sakashita K; Muramatsu H; Hama A; Takahashi Y; Koike K; Kojima S; Sugita K; Inukai T
Pediatr Transplant; 2019 May; 23(3):e13378. PubMed ID: 30786117
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Study on Treatment of Juvenile Myelomonocytic Leukemia with Haploidentical-Hematopoietic Stem Cell Transplantation].
Ding L; Zhu H; Han DM; Wang ZD; Zheng XL; Dong L; Yan HM; Liu J; Zhu L; Xue M; Guo ZK; Wang HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1524-1527. PubMed ID: 29070137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
